FIPB to clear pharma FDI till Act is changed

Foreign investment proposals in will go to the Foreign Investment Promotion Board (FIPB) for approval till the is amended.

This means that the status quo has been maintained for brownfield pharma projects. “Every proposal for foreign investment in existing Indian pharmaceutical companies will go to till the time the Competition Act is amended,” a source said.

The decision was taken at a meeting called by Prime Minister on Monday to formalise norms for pharma foreign direct investment (FDI) policy, according to sources. Finance Minister P Chidambaram, Commerce and Industry Minister and Health Minister Ghulam Nabi Azad, among others, were present at the high-level meeting, they said.

On Monday’s meeting was called to decide on two important issues in the pharma policy - the limit to which foreign companies will be allowed to acquire shares in a domestic company and the role of Competition Commission of India (CCI) in mergers and acquisitions.

While the finance ministry wants only those cases involving beyond 49 per cent in units to be considered by FIPB, commerce ministry favours all foreign investments in pharma units to be approved by FIPB.

The issue was taken up by the government after the acquisition of big Indian companies — including Ranbaxy, Shanta Biotech and Piramal Health Care’s health unit - by foreign companies. The domestic industry is apprehensive that the entry of foreign players in the Indian market may impact the availability of generic medicines as the overseas companies would focus on costly patented medicines.

image
Business Standard
177 22
Business Standard

FIPB to clear pharma FDI till Act is changed

BS Reporter  |  New Delhi 

Foreign investment proposals in will go to the Foreign Investment Promotion Board (FIPB) for approval till the is amended.

This means that the status quo has been maintained for brownfield pharma projects. “Every proposal for foreign investment in existing Indian pharmaceutical companies will go to till the time the Competition Act is amended,” a source said.

The decision was taken at a meeting called by Prime Minister on Monday to formalise norms for pharma foreign direct investment (FDI) policy, according to sources. Finance Minister P Chidambaram, Commerce and Industry Minister and Health Minister Ghulam Nabi Azad, among others, were present at the high-level meeting, they said.

On Monday’s meeting was called to decide on two important issues in the pharma policy - the limit to which foreign companies will be allowed to acquire shares in a domestic company and the role of Competition Commission of India (CCI) in mergers and acquisitions.

While the finance ministry wants only those cases involving beyond 49 per cent in units to be considered by FIPB, commerce ministry favours all foreign investments in pharma units to be approved by FIPB.

The issue was taken up by the government after the acquisition of big Indian companies — including Ranbaxy, Shanta Biotech and Piramal Health Care’s health unit - by foreign companies. The domestic industry is apprehensive that the entry of foreign players in the Indian market may impact the availability of generic medicines as the overseas companies would focus on costly patented medicines.

RECOMMENDED FOR YOU

FIPB to clear pharma FDI till Act is changed

Foreign investment proposals in pharma companies will go to the Foreign Investment Promotion Board (FIPB) for approval till the Competition Commission of India Act is amended.

Foreign investment proposals in will go to the Foreign Investment Promotion Board (FIPB) for approval till the is amended.

This means that the status quo has been maintained for brownfield pharma projects. “Every proposal for foreign investment in existing Indian pharmaceutical companies will go to till the time the Competition Act is amended,” a source said.

The decision was taken at a meeting called by Prime Minister on Monday to formalise norms for pharma foreign direct investment (FDI) policy, according to sources. Finance Minister P Chidambaram, Commerce and Industry Minister and Health Minister Ghulam Nabi Azad, among others, were present at the high-level meeting, they said.

On Monday’s meeting was called to decide on two important issues in the pharma policy - the limit to which foreign companies will be allowed to acquire shares in a domestic company and the role of Competition Commission of India (CCI) in mergers and acquisitions.

While the finance ministry wants only those cases involving beyond 49 per cent in units to be considered by FIPB, commerce ministry favours all foreign investments in pharma units to be approved by FIPB.

The issue was taken up by the government after the acquisition of big Indian companies — including Ranbaxy, Shanta Biotech and Piramal Health Care’s health unit - by foreign companies. The domestic industry is apprehensive that the entry of foreign players in the Indian market may impact the availability of generic medicines as the overseas companies would focus on costly patented medicines.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard